Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most undervalued NASDAQ stocks to buy. Its experimental medicine garetosmab met the primary endpoint in a phase 3 trial for fibrodysplasia ossificans progressiva. Both dosages decreased new bone lesions by 90% in 56 weeks compared to a placebo.

The Independent Data Monitoring Committee recommended switching placebo patients to garetosmab immediately due to safety and efficacy. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) plans to submit the medication for regulatory approval in the US by the end of 2025, with global submissions following in the next year.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biopharmaceutical company focusing on medicines for cancer, eye disorders, and allergies. While REGN shows investment potential, some AI stocks may offer greater upside and lower downside risk. For an undervalued AI stock benefiting from tariffs and onshoring, check out the best short-term AI stock.

Disclosure: None. Original article published at Insider Monkey.

Read more at Yahoo Finance: Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease